At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
SIM01dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Open-label Clinical Study to Evaluate the Effect of SIM01 in Female Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
In Brief
A clinical study evaluating SIM01 for Non-Alcoholic Fatty Liver Disease. Completed, enrolled 40 participants across 1 site.
Detailed Summary
Non-alcoholic fatty liver disease is one of the most common chronic liver diseases worldwide. Available data indicates that probiotics may regulate the gut microbiota and improve liver function in females with non-alcoholic fatty liver disease. In this study, we aim to investigate if the synbiotics (prebiotics and probiotics) are efficacious subjects in liver function improvement in female subjects with Non-alcoholic fatty liver disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Alcoholic Fatty Liver Disease
CountriesHong Kong
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartMar 2023
First PostedJun 2023
Primary CompletionOct 2023
Study CompletionDec 2023
TodayJul 2026
First PostedJun 1, 2023
Enrollment StartMar 1, 2023
Primary CompletionOct 31, 2023
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.1 years ago
Interventions
SIM01dietary
SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics